To access this element change to forms mode OFF
Grant Award View - GA218113
Inhaled Oxytocin for Improved Maternal Health in Australia & Globally
GA ID:
GA218113
Agency:
Department of Industry, Science and Resources
Approval Date:
30-Aug-2021
Publish Date:
16-Feb-2022
Category:
Business Development
Grant Term:
16-Feb-2022 to 28-Dec-2028
Original: 16-Feb-2022 to 9-Jun-2023
Value (AUD):
$490,222.00
(GST inclusive where applicable)
Variations:
- GA218113-V2 - Extension of grant term (13-Sep-2022 )
- GA218113-V1 - Correction to grant award details (15-Jul-2022 )
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DISR 21/22 Growing innovative & competitive bus, industries & regions
Grant Program:
Entrepreneurs' Programme - Accelerating Commercialisation
Grant Activity:
Inhaled Oxytocin for Improved Maternal Health in Australia & Globally
Purpose:
Monash University has developed an innovative dry particle formulation of inhaled oxytocin for the management of postpartum haemorrhage, the leading cause of maternal mortality. Inhaled oxytocin will address postpartum haemorrhage, and consequent morbidity and mortality, through an improved/simplified delivery system for the gold standard therapy. Accelerating Commercialisation support will be used to allow Monash University to complete development and commercialise Inhaled oxytocin to sell to the global market.
GO ID:
GO Title:
Entrepreneurs' Programme - Accelerating Commercialisation
Internal Reference ID:
ACGRANT000892
Selection Process:
Open Non-competitive
Confidentiality - Contract:
No
Confidentiality - Outputs:
No
Grant Recipient Details
Recipient Name:
MONASH UNIVERSITY
Recipient ABN:
12 377 614 012
Grant Recipient Location
Suburb:
MULGRAVE
Town/City:
MULGRAVE
Postcode:
3170
State/Territory:
VIC
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
SA
Postcode:
5007
Country:
AUSTRALIA